^
Association details:
| Biomarker: | EGFR exon 21 mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Vizimpro (dacomitinib) (pan-HER inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A novel EGFR exon 21 indel mutation in lung adenocarcinoma and response to dacomitinib: A case report
Published date:
08/26/2022
Excerpt:
A 59-year-old nonsmoking Chinese male was admitted to the hospital with lung cancer….The patient had clinical manifestations of cough and sputum and was pathologically confirmed to have T2bN1M0 (stage IIB) lung adenocarcinoma….After detection of the EGFR exon 21 indel mutation, the patient began treatment with dacomitinib (45 mg once a day) on March 12, 2021....After 1 month of targeted therapy, the patient showed a partial response to dacomitinib. As of March 19, 2022, his condition remained stable and he continued to receive dacomitinib. Progression-free survival reached 12.4 months.
DOI:
10.1097/MD.0000000000030269
